CA 15-3 in patients with locoregional and metastatic breast carcinoma

Geraghty, James; Coveney, Eamonn; Sherry, F.; O’Higgins, N.; Dufy, M. J.

doi:10.1002/1097-0142(19921215)70:12<2831::aid-cncr2820701218>3.0.co;2-8

Cited by 55 publications

(26 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The CA 15-3 sensitivity in our series was close to that reported elsewhere (Safi et al, 1989;de Wit et al, 1992;Geraghty et al, 1992;Bombardieri et al, 1993;Hayes, 1993;Soletormos et al, 1993). We also confirmed the finding (Clark et al, 1987) that some initial prognostic characteristics of the primary tumour, such as ER status, remain to be significant for the development of subsequent metastases.…”

Section: Discussionmentioning

confidence: 93%

Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease

Tampellini¹,

Berruti²,

Gerbino³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

In order to study the relationship between circulating levels of CA 15-3 and the disease extent in predicting survival, we prospectively followed 312 breast cancer (BC) patients, from October 1988 to March 1995, from the time of first relapse. CA 15-3 values were assessed before treatment onset. Disease extent was defined as the percentage of liver or lung involvement and the number of bone segments positive at scintigraphy. The covariates were primary tumour characteristics (T, N and hormone receptor status) and patient characteristics at recurrence (menopause, performance status and age). Higher CA 15-3 serum levels were found in patients with visceral metastases or with pleural effusion. A logistic regression model selected disease extent in liver, lung and bone as independent variables for the determination of abnormal CA 15-3 values. Univariate survival analysis confirmed the positive prognostic influence of low CA 15-3 serum levels, absence of visceral metastases and the presence of only one metastatic site. Multivariate Cox's survival analysis selected disease extent in liver, lung, bone and soft tissue but not level of CA 15-3 as prognostic factors. In conclusion, CA 15-3 is not an independent variable in determining survival, its prognostic role being linked to the disease extent. This association suggests that CA 15-3 may be useful in assessing disease extent when this is not easily assessable.

show abstract

Section: Discussionmentioning

confidence: 93%

Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease

Tampellini¹,

Berruti²,

Gerbino³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…In fact, we demonstrated a continuous increase of the marker in patients with metastatic disease that had subsequently developed locoregional relapse by analyzing CA 15-3 serum concentrations in breast cancer patients during follow-up. Similar observations were reported by different authors [23][24][25][26][27]. For example, Geraghty and coll.…”

Section: Discussionmentioning

confidence: 99%

Clinical Usefulness of Cancer Antigen 15-3 in Breast Cancer Patients Before and After Surgery

Daniele

Divella

Trerotoli

et al. 2013

TOBCANJ

View full text Add to dashboard Cite

Abstract:Background: Cancer Antigen 15-3 (CA 15-3) is a tumor-associated antigen used as serum marker for breast cancer surveillance in patients and for monitoring the response to treatment. Aim of this study was to retrospectively evaluate CA 15-3 as a prognostic factor in early detection of breast cancer relapse as well as to analyze the statistical correlation between CA 15-3 levels and clinical-pathological parameters including staging, grading, estrogen and progesterone receptors.Methods: Sera of 726 women with breast carcinoma obtained preoperatively and postoperatively were assayed for CA 15-3 by chemoluminescent immunometric assay.Results: We found that the mean serum CA 15-3 levels in patients before surgery were significantly higher (36.59 U/ml) compared with those of CA 15-3 after surgery (27.11 U/ml). We also found that elevated preoperative serum levels of CA 15-3 were significantly correlated with the presence of metastatic disease. In particular, among 305/700 patients (43,6%) that displayed over cut-off (>40U/ml) preoperative levels of CA 15-3, 94 patients (30,8%) developed advanced disease (metastases to distant sites). By contrast, in a subgroup of 395/700 patients (56.4%) with CA 15.3 serum levels < 40U/ml, only 32/305 patients (8%) showed signs of advanced disease during follow-up. Cox regression analysis revealed that only the presence of metastasis and the increased serum levels of CA 15-3 after surgery are significant risk factors for relapse of disease.Conclusion: Elevated preoperative concentrations of CA 15-3 may be a useful predictive factor for cancer progression in postoperative patients.

show abstract

“…[26][27][28][29] Highest detection rates are found in patients with bone or liver metastases. In contrast, biomarkers are rarely increased in patients with locoregional recurrences or lung-only metastasis.…”

Section: Traditional Protein Biomarkersmentioning

confidence: 99%

Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA

2018

View full text Add to dashboard Cite

Biomarkers are the key to personalized treatment in patients with breast cancer. While tissue biomarkers are most useful in determining prognosis and upfront predicting response to therapy, circulating protein biomarkers such as CA 15-3 and carcinoembryonic antigen are mainly used in monitoring response to endocrine or chemotherapy in patients with advanced disease. Although several centers measure biomarkers in asymptomatic patients following curative surgery for primary breast cancer, the clinical utility of this practice is unclear. Promising new biomarkers for breast cancer include circulating tumor DNA and circulating tumor cells. In contrast to circulating protein biomarkers, measurement of circulating tumor DNA-based biomarkers is potentially useful in identifying mechanisms of resistance to ongoing therapies as well as identifying new targets for further treatment. To increase clinical utility, both the established and emerging circulating biomarkers should where possible be incorporated into randomized trials evaluating new therapies in patients with breast cancer.

show abstract

CA 15-3 in patients with locoregional and metastatic breast carcinoma

Cited by 55 publications

References 9 publications

Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease

Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease

Clinical Usefulness of Cancer Antigen 15-3 in Breast Cancer Patients Before and After Surgery

Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA

Contact Info

Product

Resources

About